US 11,884,944 B2
Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
Tina Giese, South San Francisco, CA (US); Gunasekaran Kannan, Daly City, CA (US); Mihalis S. Kariolis, San Mateo, CA (US); and Cathal S. Mahon, San Francisco, CA (US)
Assigned to DENALI THERAPEUTICS INC., South San Francisco, CA (US)
Filed by DENALI THERAPEUTICS INC., South San Francisco, CA (US)
Filed on Jun. 30, 2022, as Appl. No. 17/855,543.
Application 17/855,543 is a continuation of application No. PCT/US2021/054860, filed on Oct. 13, 2021.
Claims priority of provisional application 63/091,800, filed on Oct. 14, 2020.
Prior Publication US 2023/0062800 A1, Mar. 2, 2023
Int. Cl. C07K 14/00 (2006.01); C12N 9/14 (2006.01); A61P 3/00 (2006.01); A61K 38/46 (2006.01)
CPC C12N 9/14 (2013.01) [A61K 38/46 (2013.01); A61P 3/00 (2018.01); C12Y 310/01001 (2013.01); C07K 2319/30 (2013.01)] 39 Claims
 
1. A protein comprising:
a. a first fusion polypeptide comprising a first Fc polypeptide linked to a first N-sulfoglucosamine sulfohydrolase (SGSH) amino acid sequence, wherein the first fusion polypeptide comprises any one of SEQ ID NOs: 65-68; and
b. a second fusion polypeptide comprising a second Fc polypeptide linked to a second SGSH amino acid sequence, wherein the second fusion polypeptide comprises any one of SEQ ID NOs: 93-96.